Pub Date : 2025-10-10DOI: 10.2174/0118715303405254250928181948
Hongtao Li, Hongyu Pan, Minshan Feng
Introduction: Traditional Chinese medicine, especially Bushen Huoxue decoction, has demonstrated good therapeutic effects in the treatment of intervertebral disc degeneration and osteoarthritis, but its mechanism of action in osteoporosis remains unclear. This study aimed to explore its potential mechanisms against osteoporosis.
Methods: Active components of Bushen Huoxue decoction were identified through searching the TCM databases. Osteoporosis-related genes were retrieved from three disease databases. Common targets were used to construct a PPI network. Functional enrichment analyses (GO and KEGG), molecular docking, molecular dynamics simulations, and literature validation were performed.
Results: A total of 112 active compounds and 343 potential targets were identified. Key bioactive ingredients included quercetin, luteolin, kaempferol, wogonin, and baicalein. The decoction appeared to act via multiple pathways, such as TNF, NF-κB, MAPK, PI3K/Akt, Wnt/β-catenin, HIF-1, FoxO, AMPK, mTOR, and VEGF, affecting inflammation, metabolism, cell proliferation, survival, and angiogenesis.
Discussion: Bushen Huoxue decoction likely exerted anti-osteoporotic effects through a multi-component, multi-target, and multi-pathway approach, consistent with current understanding of osteoporosis mechanisms. However, as this study was based on network pharmacology and computational analysis, experimental validation is needed.
Conclusion: Bushen Huoxue decoction showed promise as a potential treatment for osteoporosis through complex regulatory mechanisms. The findings provided a theoretical basis for further pharmacological research and TCM-based drug development.
{"title":"Network Pharmacology and Molecular Docking Reveal the Multi-Target Anti-Osteoporosis Mechanism of Bushen Huoxue Decoction.","authors":"Hongtao Li, Hongyu Pan, Minshan Feng","doi":"10.2174/0118715303405254250928181948","DOIUrl":"https://doi.org/10.2174/0118715303405254250928181948","url":null,"abstract":"<p><strong>Introduction: </strong>Traditional Chinese medicine, especially Bushen Huoxue decoction, has demonstrated good therapeutic effects in the treatment of intervertebral disc degeneration and osteoarthritis, but its mechanism of action in osteoporosis remains unclear. This study aimed to explore its potential mechanisms against osteoporosis.</p><p><strong>Methods: </strong>Active components of Bushen Huoxue decoction were identified through searching the TCM databases. Osteoporosis-related genes were retrieved from three disease databases. Common targets were used to construct a PPI network. Functional enrichment analyses (GO and KEGG), molecular docking, molecular dynamics simulations, and literature validation were performed.</p><p><strong>Results: </strong>A total of 112 active compounds and 343 potential targets were identified. Key bioactive ingredients included quercetin, luteolin, kaempferol, wogonin, and baicalein. The decoction appeared to act via multiple pathways, such as TNF, NF-κB, MAPK, PI3K/Akt, Wnt/β-catenin, HIF-1, FoxO, AMPK, mTOR, and VEGF, affecting inflammation, metabolism, cell proliferation, survival, and angiogenesis.</p><p><strong>Discussion: </strong>Bushen Huoxue decoction likely exerted anti-osteoporotic effects through a multi-component, multi-target, and multi-pathway approach, consistent with current understanding of osteoporosis mechanisms. However, as this study was based on network pharmacology and computational analysis, experimental validation is needed.</p><p><strong>Conclusion: </strong>Bushen Huoxue decoction showed promise as a potential treatment for osteoporosis through complex regulatory mechanisms. The findings provided a theoretical basis for further pharmacological research and TCM-based drug development.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-08DOI: 10.2174/0118715303387982250905154258
Thanh Doan Kim, To Tran Ke, Anh Tran Cong, Tuan Le Minh, Gianna Di Palma, Luigi Santacroce, Kieu Cd Nguyen, Ciro Gargiulo Isacco
Introduction: To evaluate the effectiveness of selective laser trabeculoplasty (SLT) in lowering intraocular pressure (IOP) in Vietnamese patients with pseudoexfoliation glaucoma (PXG).
Methods: This prospective, comparative study included a total of 64 eyes from PXG patients who had not previously received any antiglaucomatous medication. Patients were categorized into two groups: Group 1 consisted of 32 eyes treated with SLT as the initial therapy, while Group 2 comprised 32 eyes treated with Tafluprost 0.0015%.
Results: The baseline IOP before treatment ranged from 22 to 26 mmHg. There were no significant differences between the two groups in terms of mean cup/disc (C/D) ratio and retinal nerve fiber layer (RNFL) thickness. At the final visit, the mean percentage reduction of IOP was 26.73% in Group 1 and 27.15% in Group 2.
Discussion: SLT significantly reduced IOP in PXG patients, with outcomes comparable to Tafluprost. Treatment was more successful in eyes with higher trabecular pigmentation and early- stage glaucoma. Structural and functional parameters remained stable over 12 months. Side effects, including mild itchiness, IOP spikes, and anterior chamber reactions, were transient and manageable. No vision-threatening complications occurred, confirming SLT as a safe and effective first-line option for PXG in Vietnamese patients.
Conclusion: SLT can be effectively used as a primary treatment for PXG. In cases of recurrent IOP elevation, a second SLT procedure can be administered alone or in combination with other medications.
{"title":"Pseudoexfoliation Glaucoma Selective Laser for Trabeculoplasty Treatment in Vietnam.","authors":"Thanh Doan Kim, To Tran Ke, Anh Tran Cong, Tuan Le Minh, Gianna Di Palma, Luigi Santacroce, Kieu Cd Nguyen, Ciro Gargiulo Isacco","doi":"10.2174/0118715303387982250905154258","DOIUrl":"https://doi.org/10.2174/0118715303387982250905154258","url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate the effectiveness of selective laser trabeculoplasty (SLT) in lowering intraocular pressure (IOP) in Vietnamese patients with pseudoexfoliation glaucoma (PXG).</p><p><strong>Methods: </strong>This prospective, comparative study included a total of 64 eyes from PXG patients who had not previously received any antiglaucomatous medication. Patients were categorized into two groups: Group 1 consisted of 32 eyes treated with SLT as the initial therapy, while Group 2 comprised 32 eyes treated with Tafluprost 0.0015%.</p><p><strong>Results: </strong>The baseline IOP before treatment ranged from 22 to 26 mmHg. There were no significant differences between the two groups in terms of mean cup/disc (C/D) ratio and retinal nerve fiber layer (RNFL) thickness. At the final visit, the mean percentage reduction of IOP was 26.73% in Group 1 and 27.15% in Group 2.</p><p><strong>Discussion: </strong>SLT significantly reduced IOP in PXG patients, with outcomes comparable to Tafluprost. Treatment was more successful in eyes with higher trabecular pigmentation and early- stage glaucoma. Structural and functional parameters remained stable over 12 months. Side effects, including mild itchiness, IOP spikes, and anterior chamber reactions, were transient and manageable. No vision-threatening complications occurred, confirming SLT as a safe and effective first-line option for PXG in Vietnamese patients.</p><p><strong>Conclusion: </strong>SLT can be effectively used as a primary treatment for PXG. In cases of recurrent IOP elevation, a second SLT procedure can be administered alone or in combination with other medications.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-03DOI: 10.2174/0118715303369433250914053054
Yi Wei, Chao Liu, Jiangyi Yu
Introduction: The relationship between uric acid to high-density cholesterol ratio (UHR) and diabetic kidney disease (DKD) is unclear. The aim of this study was to investigate the relationship between UHR and DKD in patients with diabetes mellitus (DM).
Methods: Analyses were conducted based on National Health and Nutrition Examination Survey (NHANES) data from the 2007-2018 cycle. We used multifactorial logistic regression to analyze the association between UHR and DKD. We performed restricted cubic splines (RCS) analyses to explore whether there was a nonlinear relationship between the two. In addition, we explored differences in this association between different subgroups.
Results: A total of 2,674 participants were included in the study. After adjusting for all confounding variables, multivariate logistic regression analysis revealed a significant correlation between UHR and DKD in patients with DM. RCS analysis further revealed a significant nonlinear association between UHR and DKD. Subgroup analysis showed that the association between UHR and DKD was consistent across different subgroups. In addition, the effect of UHR on DKD was significantly influenced by the level of BMI.
Discussion: This study explored the relationship between UHR and DKD, contributing to a better understanding of the significance of UHR in DKD.
Conclusion: Our study found a "J" nonlinear association between UHR and DKD in patients with DM.
{"title":"Nonlinear Association Between Uric Acid to High-Density Lipoprotein Cholesterol Ratio and Diabetic Kidney Disease: Evidence from NHANES 2007-2018.","authors":"Yi Wei, Chao Liu, Jiangyi Yu","doi":"10.2174/0118715303369433250914053054","DOIUrl":"https://doi.org/10.2174/0118715303369433250914053054","url":null,"abstract":"<p><strong>Introduction: </strong>The relationship between uric acid to high-density cholesterol ratio (UHR) and diabetic kidney disease (DKD) is unclear. The aim of this study was to investigate the relationship between UHR and DKD in patients with diabetes mellitus (DM).</p><p><strong>Methods: </strong>Analyses were conducted based on National Health and Nutrition Examination Survey (NHANES) data from the 2007-2018 cycle. We used multifactorial logistic regression to analyze the association between UHR and DKD. We performed restricted cubic splines (RCS) analyses to explore whether there was a nonlinear relationship between the two. In addition, we explored differences in this association between different subgroups.</p><p><strong>Results: </strong>A total of 2,674 participants were included in the study. After adjusting for all confounding variables, multivariate logistic regression analysis revealed a significant correlation between UHR and DKD in patients with DM. RCS analysis further revealed a significant nonlinear association between UHR and DKD. Subgroup analysis showed that the association between UHR and DKD was consistent across different subgroups. In addition, the effect of UHR on DKD was significantly influenced by the level of BMI.</p><p><strong>Discussion: </strong>This study explored the relationship between UHR and DKD, contributing to a better understanding of the significance of UHR in DKD.</p><p><strong>Conclusion: </strong>Our study found a \"J\" nonlinear association between UHR and DKD in patients with DM.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-02DOI: 10.2174/0118715303385546250912094219
Xiong Ying Li, Ru Meng Yao, Xiao Ming Zou, Yun Xu, Sha Ying Qiu, Ping Ping He, Li Jun Wang, Shan Shan Lei
Introduction: Achyranthes bidentata Blume (AB), a traditional Chinese medicine, is used to treat Non-alcoholic fatty liver disease (NAFLD), although its precise mechanism of action remains unclear. This study investigated the effects of Achyranthes bidentata water extract (ABW) on NAFLD in mice induced by high-fat-fed.
Methods: The chemical components of Achyranthes bidentata Blume water extract (ABW) were analyzed using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). After 12 weeks of ABW treatment, liver histopathology and hepatic lipid levels, including total cholesterol (TC) and triglycerides (TG), were evaluated in NAFLD mice. Enzyme-linked immunosorbent assay, quantitative PCR, western blotting, and immunofluorescence were employed to assess changes in the PPARγ/LXRα signaling pathway and macrophage efferocytosis in vivo and in vitro.
Results: In vivo, ABW treatment significantly reduced hepatic lipid accumulation (TC and TG) and alleviated hepatic lesions compared with the model group. ABW also upregulated genes associated with lipid metabolism and macrophage efferocytosis, while reducing the hepatic levels of inflammatory cytokines and the number of apoptotic cells. In vitro, ABW suppressed the expression of pro-inflammatory genes (Il1b, Il6, Tnf, and Nos2) and enhanced the expression of macrophage efferocytosis-related genes (Pparγ, Gas6, Tyro3, and Axl) in ox-LDL-induced Raw 264.7 cells. UHPLC-MS identified 501 compounds in ABW. Auto-docking analysis suggested that 4-dodecylbenzenesulfonic acid, isovanilic acid, and oleanolic acid are potential PPARγ activators present in ABW.
Discussion: This study demonstrates that ABW ameliorates NAFLD by activating the PPARγ/LXRα signaling pathway and promoting macrophage efferocytosis.
Conclusion: These findings provide a novel mechanistic insight into the therapeutic effects of multi- component herbal medicines for NAFLD.
{"title":"Mechanistic Insights into <i>Achyranthes Bidentata</i> Blume Water Extract in Alleviating NAFLD: PPARγ-Driven Synergistic Regulation of Lipid Metabolism and Macrophage Efferocytosis.","authors":"Xiong Ying Li, Ru Meng Yao, Xiao Ming Zou, Yun Xu, Sha Ying Qiu, Ping Ping He, Li Jun Wang, Shan Shan Lei","doi":"10.2174/0118715303385546250912094219","DOIUrl":"https://doi.org/10.2174/0118715303385546250912094219","url":null,"abstract":"<p><strong>Introduction: </strong>Achyranthes bidentata Blume (AB), a traditional Chinese medicine, is used to treat Non-alcoholic fatty liver disease (NAFLD), although its precise mechanism of action remains unclear. This study investigated the effects of <i>Achyranthes bidentata</i> water extract (ABW) on NAFLD in mice induced by high-fat-fed.</p><p><strong>Methods: </strong>The chemical components of Achyranthes bidentata Blume water extract (ABW) were analyzed using ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). After 12 weeks of ABW treatment, liver histopathology and hepatic lipid levels, including total cholesterol (TC) and triglycerides (TG), were evaluated in NAFLD mice. Enzyme-linked immunosorbent assay, quantitative PCR, western blotting, and immunofluorescence were employed to assess changes in the PPARγ/LXRα signaling pathway and macrophage efferocytosis in vivo and in vitro.</p><p><strong>Results: </strong>In vivo, ABW treatment significantly reduced hepatic lipid accumulation (TC and TG) and alleviated hepatic lesions compared with the model group. ABW also upregulated genes associated with lipid metabolism and macrophage efferocytosis, while reducing the hepatic levels of inflammatory cytokines and the number of apoptotic cells. <i>In vitro</i>, ABW suppressed the expression of pro-inflammatory genes (<i>Il1b, Il6, Tnf, and Nos2</i>) and enhanced the expression of macrophage efferocytosis-related genes (<i>Pparγ, Gas6, Tyro3, and Axl</i>) in ox-LDL-induced Raw 264.7 cells. UHPLC-MS identified 501 compounds in ABW. Auto-docking analysis suggested that 4-dodecylbenzenesulfonic acid, isovanilic acid, and oleanolic acid are potential PPARγ activators present in ABW.</p><p><strong>Discussion: </strong>This study demonstrates that ABW ameliorates NAFLD by activating the PPARγ/LXRα signaling pathway and promoting macrophage efferocytosis.</p><p><strong>Conclusion: </strong>These findings provide a novel mechanistic insight into the therapeutic effects of multi- component herbal medicines for NAFLD.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-02DOI: 10.2174/0118715303411821250914094338
Mohammad Hady Khosravi, Khairollah Asadollahi, Bahareh Ghiasi, Amir Adibi, Somayeh Heidarizadi, Monireh Azizi
Introduction: Valproic acid (VPA), a widely used antiepileptic drug, is associated with pancreatic toxicity. Silibinin, the active component of silymarin, exhibits antioxidant/anti-inflammatory properties. This study investigated silibinin's protective effects against VPA-induced pancreatitis.
Methods: 48 male Wistar rats (250-280 g) were divided into 8 groups (n=6): control, VPA-only (150,300 and 450 mg/kg), silibinin-only (150 mg/kg), and co-treatment groups. After 3 weeks, biochemical markers (amylase, lipase, SOD, CAT, TNF-α, IL-6) and histopathology (H&E staining) were analyzed. Data were compared using ANOVA/Tukey's test (p<0.05 significant).
Results: VPA dose-dependently increased pancreatic enzymes and inflammatory markers, while reducing antioxidants. Silibinin co-treatment significantly attenuated these effects: Reduced amylase (642.8→375.6 U/L at 450 mg/kg VPA) and TNF-α (61.0→31.6 pg/mL) and restored SOD (10.9→18.3 U/mg) and CAT (5.3→366.2 U/mg). Histopathology confirmed reduced inflammation/ necrosis in co-treatment groups (p<0.01).
Discussion: Silibinin mitigated VPA-induced pancreatitis via antioxidant (SOD/CAT upregulation) and anti-inflammatory (TNF-α/IL-6 reduction) mechanisms. The effect was dose-dependent, with optimal protection at lower VPA doses (150 and 300 mg/kg).
Conclusion: Silibinin shows promise as an adjunct therapy to reduce VPA-associated pancreatic damage. Further clinical studies are warranted.
{"title":"Anti-inflammatory and Antioxidant Effects of Silibinin on Valproate-Induced Pancreatitis in Male Wistar Rats.","authors":"Mohammad Hady Khosravi, Khairollah Asadollahi, Bahareh Ghiasi, Amir Adibi, Somayeh Heidarizadi, Monireh Azizi","doi":"10.2174/0118715303411821250914094338","DOIUrl":"https://doi.org/10.2174/0118715303411821250914094338","url":null,"abstract":"<p><strong>Introduction: </strong>Valproic acid (VPA), a widely used antiepileptic drug, is associated with pancreatic toxicity. Silibinin, the active component of silymarin, exhibits antioxidant/anti-inflammatory properties. This study investigated silibinin's protective effects against VPA-induced pancreatitis.</p><p><strong>Methods: </strong>48 male Wistar rats (250-280 g) were divided into 8 groups (n=6): control, VPA-only (150,300 and 450 mg/kg), silibinin-only (150 mg/kg), and co-treatment groups. After 3 weeks, biochemical markers (amylase, lipase, SOD, CAT, TNF-α, IL-6) and histopathology (H&E staining) were analyzed. Data were compared using ANOVA/Tukey's test (p<0.05 significant).</p><p><strong>Results: </strong>VPA dose-dependently increased pancreatic enzymes and inflammatory markers, while reducing antioxidants. Silibinin co-treatment significantly attenuated these effects: Reduced amylase (642.8→375.6 U/L at 450 mg/kg VPA) and TNF-α (61.0→31.6 pg/mL) and restored SOD (10.9→18.3 U/mg) and CAT (5.3→366.2 U/mg). Histopathology confirmed reduced inflammation/ necrosis in co-treatment groups (p<0.01).</p><p><strong>Discussion: </strong>Silibinin mitigated VPA-induced pancreatitis via antioxidant (SOD/CAT upregulation) and anti-inflammatory (TNF-α/IL-6 reduction) mechanisms. The effect was dose-dependent, with optimal protection at lower VPA doses (150 and 300 mg/kg).</p><p><strong>Conclusion: </strong>Silibinin shows promise as an adjunct therapy to reduce VPA-associated pancreatic damage. Further clinical studies are warranted.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-25DOI: 10.2174/0118715303396515250912001734
Binwei Qiu, Yan Lin
Introduction: To examine the relationship between mercury exposure and serum sex steroid hormones among children aged 6-18 years.
Methods: Data were collected from the NHANES 2013-2016. A cohort of 2,637 Children with available information on mercury exposure, serum sex steroid hormones, and covariates was enrolled. Generalized linear models were applied to explore the association of mercury exposure with sex steroid hormones. Finally, we adopted the Bayesian kernel machine regression (BKMR) model to investigate the effect of mixture exposure to mercury on hormone levels.
Results: Methyl mercury (MeHg) and total mercury (Hg) were associated with all sex steroid hormones except E2 (P <0.05). After adjusting for covariates, MeHg and Hg were related to sex hormone- binding globulin (SHBG) and free androgen index (FAI) (P <0.05). Stratified analysis by sex-puberty revealed a negative relationship between Hg and SHBG, while a positive association of MeHg with FAI in prepubertal girls (P <0.05). Their associations were confirmed by the BKMR model analysis, in which the mixture exposure was positively linked to FAI but inversely related to SHBG, particularly among prepubertal girls.
Discussion: These findings suggest that mercury may disrupt sex hormone homeostasis during critical developmental windows. Appropriate measures should be implemented to mitigate the adverse effects of mercury on sex hormones in the young population. However, future longitudinal large-scale studies are required for validation.
Conclusion: Exposure to MeHg and Hg is associated with increased FAI levels, but decreased levels of SHBG, which are more pronounced in girls. The heightened susceptibility of prepubertal girls underscores the need for targeted public health interventions, including dietary guidance on seafood consumption and early biomonitoring of mercury levels in high-risk populations, to mitigate potential health impacts.
{"title":"Associations of Mercury Exposure with Serum Sex Steroid Hormones in Children 6-18 Years from NHANES 2013-2016.","authors":"Binwei Qiu, Yan Lin","doi":"10.2174/0118715303396515250912001734","DOIUrl":"https://doi.org/10.2174/0118715303396515250912001734","url":null,"abstract":"<p><strong>Introduction: </strong>To examine the relationship between mercury exposure and serum sex steroid hormones among children aged 6-18 years.</p><p><strong>Methods: </strong>Data were collected from the NHANES 2013-2016. A cohort of 2,637 Children with available information on mercury exposure, serum sex steroid hormones, and covariates was enrolled. Generalized linear models were applied to explore the association of mercury exposure with sex steroid hormones. Finally, we adopted the Bayesian kernel machine regression (BKMR) model to investigate the effect of mixture exposure to mercury on hormone levels.</p><p><strong>Results: </strong>Methyl mercury (MeHg) and total mercury (Hg) were associated with all sex steroid hormones except E2 (P <0.05). After adjusting for covariates, MeHg and Hg were related to sex hormone- binding globulin (SHBG) and free androgen index (FAI) (P <0.05). Stratified analysis by sex-puberty revealed a negative relationship between Hg and SHBG, while a positive association of MeHg with FAI in prepubertal girls (P <0.05). Their associations were confirmed by the BKMR model analysis, in which the mixture exposure was positively linked to FAI but inversely related to SHBG, particularly among prepubertal girls.</p><p><strong>Discussion: </strong>These findings suggest that mercury may disrupt sex hormone homeostasis during critical developmental windows. Appropriate measures should be implemented to mitigate the adverse effects of mercury on sex hormones in the young population. However, future longitudinal large-scale studies are required for validation.</p><p><strong>Conclusion: </strong>Exposure to MeHg and Hg is associated with increased FAI levels, but decreased levels of SHBG, which are more pronounced in girls. The heightened susceptibility of prepubertal girls underscores the need for targeted public health interventions, including dietary guidance on seafood consumption and early biomonitoring of mercury levels in high-risk populations, to mitigate potential health impacts.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-25DOI: 10.2174/0118715303398054250823130459
Guohua Liu, Chaozhong Zhou, Xunli Xiao, Siyuan Hu, Bo Xie, Zonghai Wu, Jun Xiao
Introduction: Quan-du-zhong capsule (QDZ), derived from Eucommia ulmoides Oliv, is clinically utilized for diabetic kidney disease (DKD) management due to its renoprotective effects. Recent studies have demonstrated that QDZ ameliorates proteinuria and attenuates the decline in glomerular filtration rate (GFR) in DKD patients; however, the underlying mechanisms remain unclear.
Methods: To elucidate the active components of QDZ and their potential association with immune cell modulation, we conducted bioinformatics analyses using GEO datasets and CIBERSORT to assess immune cell infiltration. Furthermore, molecular docking experiments and experimental validation were performed to verify the interactions between QDZ and potential immunotherapeutic targets.
Results: Network pharmacology analysis identified the main active components of QDZ, including Quercetin, Kaempferol, β-carotene, β-sitosterol, and Syringetin. Furthermore, bioinformatics and molecular docking studies demonstrated that the FOS gene and the MAPK signaling pathway exhibit differential expression in DKD patients and were significantly correlated with immune cell activity. Notably, the active components-particularly Quercetin, Kaempferol, and Syringetin- displayed strong binding affinities to key targets. In addition, QDZ significantly upregulated FOS and MAPK expression and enhanced glucose uptake in HG-induced HEK-293 cells, suggesting its role in improving insulin sensitivity.
Conclusions: This study illustrates the mechanism by which QDZ upregulates FOS expression and modulates the MAPK signaling pathway, thereby regulating immune cell function in DKD. These findings provide novel insights to inform future research and development of QDZ-based DKD therapies.
{"title":"Unraveling the Immunomodulatory Mechanisms of Quan-du-zhong Capsule in Diabetic Kidney Disease <i>via</i> Integrated Network Pharmacology and Experimental Validation.","authors":"Guohua Liu, Chaozhong Zhou, Xunli Xiao, Siyuan Hu, Bo Xie, Zonghai Wu, Jun Xiao","doi":"10.2174/0118715303398054250823130459","DOIUrl":"https://doi.org/10.2174/0118715303398054250823130459","url":null,"abstract":"<p><strong>Introduction: </strong>Quan-du-zhong capsule (QDZ), derived from <i>Eucommia ulmoides</i> Oliv, is clinically utilized for diabetic kidney disease (DKD) management due to its renoprotective effects. Recent studies have demonstrated that QDZ ameliorates proteinuria and attenuates the decline in glomerular filtration rate (GFR) in DKD patients; however, the underlying mechanisms remain unclear.</p><p><strong>Methods: </strong>To elucidate the active components of QDZ and their potential association with immune cell modulation, we conducted bioinformatics analyses using GEO datasets and CIBERSORT to assess immune cell infiltration. Furthermore, molecular docking experiments and experimental validation were performed to verify the interactions between QDZ and potential immunotherapeutic targets.</p><p><strong>Results: </strong>Network pharmacology analysis identified the main active components of QDZ, including Quercetin, Kaempferol, β-carotene, β-sitosterol, and Syringetin. Furthermore, bioinformatics and molecular docking studies demonstrated that the FOS gene and the MAPK signaling pathway exhibit differential expression in DKD patients and were significantly correlated with immune cell activity. Notably, the active components-particularly Quercetin, Kaempferol, and Syringetin- displayed strong binding affinities to key targets. In addition, QDZ significantly upregulated FOS and MAPK expression and enhanced glucose uptake in HG-induced HEK-293 cells, suggesting its role in improving insulin sensitivity.</p><p><strong>Conclusions: </strong>This study illustrates the mechanism by which QDZ upregulates FOS expression and modulates the MAPK signaling pathway, thereby regulating immune cell function in DKD. These findings provide novel insights to inform future research and development of QDZ-based DKD therapies.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: This study aimed to identify key genes and potential therapeutic targets involved in the progression of osteoarthritis (OA) through an integrated multi-omics approach.
Methods: We performed single-cell RNA sequencing (scRNA-seq) analysis on OA and control samples to define cell types and differentially expressed genes (DEGs). Bulk RNA-seq data from 7 public OA datasets were analyzed to identify DEGs, and Weighted Gene Co-expression Network Analysis (WGCNA) identified key co-expressed modules. An Integrated analysis of scRNA- seq DEGs, bulk RNA-seq DEGs, and WGCNA module genes pinpointed overlapping candidates. Functional enrichment analysis of these genes was then conducted. Mendelian randomization (MR) analysis was used to assess causal relationships between candidate genes and OA risk. The top candidate gene, CDO1, was functionally validated using siRNA-mediated knockdown in a rat OA model, assessed by histology and immunohistochemistry.
Results: scRNA-seq identified 11 distinct cell types and 4,316 DEGs. Bulk RNA-seq meta-analysis revealed 3,664 DEGs, with WGCNA highlighting a key module significantly associated with OA. Integration identified 932 overlapping DEGs. Enrichment analysis implicated pathways including ferroptosis, PI3K-Akt signaling, and ECM-receptor interaction. MR analysis established CDO1 as the top causal OA risk gene (OR [95% CI] = 0.998 [0.996-0.999], P = 0.003).
Discussion: In vivo, CDO1 knockdown significantly delayed OA progression in rats. Compared to controls, the si-CDO1 group showed improved cartilage structure, increased chondrocyte numbers, and enhanced type II collagen expression.
Conclusion: CDO1 is a novel OA risk gene and therapeutic target. Its inhibition protects against OA progression, as supported by integrated multi-omics analysis and in vivo validation.
{"title":"Integrated Multiomics Analysis Identifies CDO1 as a Novel Therapeutic Target for Osteoarthritis.","authors":"Zhihu Zhao, Xiangdong Wu, Duan Wang, Wei Luo, Jian-Xiong Ma, Xin-Long Ma","doi":"10.2174/0118715303387442250918111006","DOIUrl":"https://doi.org/10.2174/0118715303387442250918111006","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to identify key genes and potential therapeutic targets involved in the progression of osteoarthritis (OA) through an integrated multi-omics approach.</p><p><strong>Methods: </strong>We performed single-cell RNA sequencing (scRNA-seq) analysis on OA and control samples to define cell types and differentially expressed genes (DEGs). Bulk RNA-seq data from 7 public OA datasets were analyzed to identify DEGs, and Weighted Gene Co-expression Network Analysis (WGCNA) identified key co-expressed modules. An Integrated analysis of scRNA- seq DEGs, bulk RNA-seq DEGs, and WGCNA module genes pinpointed overlapping candidates. Functional enrichment analysis of these genes was then conducted. Mendelian randomization (MR) analysis was used to assess causal relationships between candidate genes and OA risk. The top candidate gene, CDO1, was functionally validated using siRNA-mediated knockdown in a rat OA model, assessed by histology and immunohistochemistry.</p><p><strong>Results: </strong>scRNA-seq identified 11 distinct cell types and 4,316 DEGs. Bulk RNA-seq meta-analysis revealed 3,664 DEGs, with WGCNA highlighting a key module significantly associated with OA. Integration identified 932 overlapping DEGs. Enrichment analysis implicated pathways including ferroptosis, PI3K-Akt signaling, and ECM-receptor interaction. MR analysis established CDO1 as the top causal OA risk gene (OR [95% CI] = 0.998 [0.996-0.999], P = 0.003).</p><p><strong>Discussion: </strong>In vivo, CDO1 knockdown significantly delayed OA progression in rats. Compared to controls, the si-CDO1 group showed improved cartilage structure, increased chondrocyte numbers, and enhanced type II collagen expression.</p><p><strong>Conclusion: </strong>CDO1 is a novel OA risk gene and therapeutic target. Its inhibition protects against OA progression, as supported by integrated multi-omics analysis and in vivo validation.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-19DOI: 10.2174/0118715303381483250629164853
Enzo Shintaku, Davi Vantini, João Gabriel Bicudo Ting, Rubén David Dos Reis Zuniga, Glaucia Luciano da Veiga, Beatriz da Costa Aguiar Alves, Jéssica Freitas Encinas, Fernando Luiz Affonso Fonseca
Introduction: Irisin is a hormone synthesized by skeletal muscle cells in response to physical exercise. It has been linked to various health benefits, including improved insulin sensitivity, fat burning, reduced inflammation, and potential protection against metabolic diseases, such as obesity and type 2 diabetes. This review explores the role of irisin, stimulated by physical exercise, in kidney diseases.
Methods: A comprehensive review was conducted using SciELO, PubMed, Scopus, Web of Science, and EMBASE. Five articles were selected based on pre-established eligibility criteria. These studies used animal experiments, assessing irisin predominantly through Western blotting or ELISA, with aerobic exercise protocols, mainly treadmill running.
Results: The results consistently showed an increase in irisin levels in response to physical exercise in animal models with kidney diseases.
Discussion: Aerobic exercise increased plasma irisin expression, with better outcomes observed with low to medium-intensity training. Irisin demonstrated therapeutic potential by reducing renal cysts, inhibiting epithelial-mesenchymal transition, decreasing markers of diabetic nephropathy, and restoring autophagy in podocytes. Additionally, it activated the AMPK-Sirt1-PGC-1α pathway, suggesting antioxidant and antiapoptotic effects.
Conclusion: The studies reviewed suggested that aerobic exercise increased irisin levels in animal models of kidney diseases, showing potential therapeutic effects for renal health.
鸢尾素是骨骼肌细胞在运动后合成的一种激素。它与各种健康益处有关,包括改善胰岛素敏感性,脂肪燃烧,减少炎症,以及对代谢疾病(如肥胖和2型糖尿病)的潜在保护。这篇综述探讨了体育锻炼刺激下鸢尾素在肾脏疾病中的作用。方法:采用SciELO、PubMed、Scopus、Web of Science、EMBASE进行综合评价。根据预先确定的资格标准选择了五篇文章。这些研究采用动物实验,主要通过免疫印迹法(Western blotting)或酶联免疫吸附试验(ELISA)评估鸢尾素,并辅以有氧运动方案,主要是跑步机。结果:结果一致表明,在肾脏疾病动物模型中,鸢尾素水平随着体育锻炼的增加而增加。讨论:有氧运动增加血浆鸢尾素表达,低至中等强度训练效果更好。鸢尾素通过减少肾囊肿、抑制上皮-间质转化、降低糖尿病肾病标志物和恢复足细胞自噬显示出治疗潜力。此外,它激活AMPK-Sirt1-PGC-1α通路,提示抗氧化和抗凋亡作用。结论:有氧运动可提高肾脏疾病动物模型中的鸢尾素水平,对肾脏健康具有潜在的治疗作用。
{"title":"Assessment of Exercise-Stimulated Irisin in Kidney Disease: A Systematic Review.","authors":"Enzo Shintaku, Davi Vantini, João Gabriel Bicudo Ting, Rubén David Dos Reis Zuniga, Glaucia Luciano da Veiga, Beatriz da Costa Aguiar Alves, Jéssica Freitas Encinas, Fernando Luiz Affonso Fonseca","doi":"10.2174/0118715303381483250629164853","DOIUrl":"https://doi.org/10.2174/0118715303381483250629164853","url":null,"abstract":"<p><strong>Introduction: </strong>Irisin is a hormone synthesized by skeletal muscle cells in response to physical exercise. It has been linked to various health benefits, including improved insulin sensitivity, fat burning, reduced inflammation, and potential protection against metabolic diseases, such as obesity and type 2 diabetes. This review explores the role of irisin, stimulated by physical exercise, in kidney diseases.</p><p><strong>Methods: </strong>A comprehensive review was conducted using SciELO, PubMed, Scopus, Web of Science, and EMBASE. Five articles were selected based on pre-established eligibility criteria. These studies used animal experiments, assessing irisin predominantly through Western blotting or ELISA, with aerobic exercise protocols, mainly treadmill running.</p><p><strong>Results: </strong>The results consistently showed an increase in irisin levels in response to physical exercise in animal models with kidney diseases.</p><p><strong>Discussion: </strong>Aerobic exercise increased plasma irisin expression, with better outcomes observed with low to medium-intensity training. Irisin demonstrated therapeutic potential by reducing renal cysts, inhibiting epithelial-mesenchymal transition, decreasing markers of diabetic nephropathy, and restoring autophagy in podocytes. Additionally, it activated the AMPK-Sirt1-PGC-1α pathway, suggesting antioxidant and antiapoptotic effects.</p><p><strong>Conclusion: </strong>The studies reviewed suggested that aerobic exercise increased irisin levels in animal models of kidney diseases, showing potential therapeutic effects for renal health.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-18DOI: 10.2174/0118715303396313250904204350
Chen Xie, Tao Liu, Yuanxin Zhong, Zhengyu Li, Ji Xu, Zijun Zhao, Xinqiang Wang, Po Gao
<p><strong>Introduction: </strong>In recent years, the prevalence of nonalcoholic steatohepatitis (NASH) has been rising globally. NASH has been linked to liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation (LT), with the progression and severity of NASH closely impacting patients' prognosis. This increasing incidence highlights the urgent need for effective therapeutic strategies and early detection methods to mitigate the progression of the disease and improve patient prognosis. Accumulating evidence indicates that NASH and diabetes mellitus (DM) are interconnected and mutually affect each other. This study utilized bibliometric analysis to assess current publication trends and focal points in the links between NASH and DM, aiming to promote research in this area.</p><p><strong>Methods: </strong>We thoroughly searched the Science Citation Index-Expanded (SCI-E) of the Web of Science Core Collection (WoSCC), PubMed, and the Excerpta Medica Database (Embase) to identify relevant articles on the links between NASH and DM from 2004 to 2023. The current publication trends and hotspots in this field were analyzed using the Online Analysis Platform of Literature Metrology, CiteSpace software, VOSviewer, and the R package Bibliometrix.</p><p><strong>Results: </strong>From 2004 to 2023, 943 articles were found that focused on the links between NASH and DM with a noticeable surge in publications since 2015. The United States has taken the primary position in terms of the number of publications. It has also been the most active country in international collaborative efforts. The University of California, San Diego, and Kenneth Cusi were the most productive institution and scholar, respectively. The co-citation keywords cluster labels revealed 10 primary clusters: adiponectin, MAFLD, mortality, NASH, nonalcoholic fatty liver, SGLT2, neurodegeneration, LY2405319, autophagy, and hepatocytes. Recent studies focused on weight loss, fibrosis stage, NAFLD, mortality, and diabetes mellitus.</p><p><strong>Discussion: </strong>Research on NASH and DM has transitioned from early mechanistic exploration to a current focus on weight management, diabetes control, and fibrosis prevention, particularly through lifestyle interventions and antidiabetic drug therapy. Future studies should integrate lifestyle adjustments with drug development, enhance international cooperation to fill regional research gaps, and achieve more effective management of NASH and DM.</p><p><strong>Conclusion: </strong>Over the past 20 years, global publications on the relationship between NASH and DM have grown rapidly. The current research hotspots focus on weight loss, and the reduction of blood glucose and fibrosis in NASH. Maintaining a healthy diet, exercising regularly, taking appropriate medication, and being vigilant about complications are essential for delaying the progression of NASH and DM. These are also the primary future directions of research.</p><p
近年来,非酒精性脂肪性肝炎(NASH)的患病率在全球呈上升趋势。NASH与肝纤维化、肝硬化、肝细胞癌(HCC)和肝移植(LT)有关,NASH的进展和严重程度密切影响患者的预后。这种增加的发病率突出了迫切需要有效的治疗策略和早期发现方法,以减缓疾病的进展和改善患者预后。越来越多的证据表明,NASH和糖尿病(DM)是相互联系和相互影响的。本研究利用文献计量学分析来评估NASH和DM之间联系的当前出版趋势和重点,旨在促进这一领域的研究。方法:全面检索Web of Science Core Collection (WoSCC)、PubMed、摘录医学数据库(Embase)的科学引文索引扩展版(SCI-E),找出2004 - 2023年NASH与DM之间联系的相关文章。利用文献计量学在线分析平台、CiteSpace软件、VOSviewer和R软件包Bibliometrix,分析了该领域当前的出版趋势和热点。结果:从2004年到2023年,共发现了943篇关注NASH和DM之间联系的文章,自2015年以来,论文数量显著增加。就出版物数量而言,美国占据了首位。它也是国际合作努力中最积极的国家。加州大学圣地亚哥分校(University of California, San Diego)和肯尼斯·库西(Kenneth Cusi)分别是最具生产力的机构和学者。共被引关键词聚类标签显示了10个主要聚类:脂联素、MAFLD、死亡率、NASH、非酒精性脂肪肝、SGLT2、神经变性、LY2405319、自噬和肝细胞。最近的研究集中在体重减轻、纤维化分期、NAFLD、死亡率和糖尿病。讨论:NASH和DM的研究已经从早期的机制探索过渡到目前的体重管理、糖尿病控制和纤维化预防,特别是通过生活方式干预和降糖药物治疗。未来的研究应将生活方式调整与药物开发结合起来,加强国际合作以填补区域研究空白,实现NASH和DM的更有效管理。结论:在过去的20年里,全球关于NASH和DM关系的出版物迅速增长。目前的研究热点集中在NASH患者的体重减轻、血糖和纤维化的降低等方面。保持健康饮食、规律运动、适当用药、警惕并发症对延缓NASH和DM进展至关重要,这也是未来研究的主要方向。注册号:1020973(普洛斯彼罗)。
{"title":"Bibliometric Analysis of Emerging Trends and Hotspots in the Links between Nonalcoholic Steatohepatitis and Diabetes Mellitus from 2004 to 2023.","authors":"Chen Xie, Tao Liu, Yuanxin Zhong, Zhengyu Li, Ji Xu, Zijun Zhao, Xinqiang Wang, Po Gao","doi":"10.2174/0118715303396313250904204350","DOIUrl":"https://doi.org/10.2174/0118715303396313250904204350","url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, the prevalence of nonalcoholic steatohepatitis (NASH) has been rising globally. NASH has been linked to liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation (LT), with the progression and severity of NASH closely impacting patients' prognosis. This increasing incidence highlights the urgent need for effective therapeutic strategies and early detection methods to mitigate the progression of the disease and improve patient prognosis. Accumulating evidence indicates that NASH and diabetes mellitus (DM) are interconnected and mutually affect each other. This study utilized bibliometric analysis to assess current publication trends and focal points in the links between NASH and DM, aiming to promote research in this area.</p><p><strong>Methods: </strong>We thoroughly searched the Science Citation Index-Expanded (SCI-E) of the Web of Science Core Collection (WoSCC), PubMed, and the Excerpta Medica Database (Embase) to identify relevant articles on the links between NASH and DM from 2004 to 2023. The current publication trends and hotspots in this field were analyzed using the Online Analysis Platform of Literature Metrology, CiteSpace software, VOSviewer, and the R package Bibliometrix.</p><p><strong>Results: </strong>From 2004 to 2023, 943 articles were found that focused on the links between NASH and DM with a noticeable surge in publications since 2015. The United States has taken the primary position in terms of the number of publications. It has also been the most active country in international collaborative efforts. The University of California, San Diego, and Kenneth Cusi were the most productive institution and scholar, respectively. The co-citation keywords cluster labels revealed 10 primary clusters: adiponectin, MAFLD, mortality, NASH, nonalcoholic fatty liver, SGLT2, neurodegeneration, LY2405319, autophagy, and hepatocytes. Recent studies focused on weight loss, fibrosis stage, NAFLD, mortality, and diabetes mellitus.</p><p><strong>Discussion: </strong>Research on NASH and DM has transitioned from early mechanistic exploration to a current focus on weight management, diabetes control, and fibrosis prevention, particularly through lifestyle interventions and antidiabetic drug therapy. Future studies should integrate lifestyle adjustments with drug development, enhance international cooperation to fill regional research gaps, and achieve more effective management of NASH and DM.</p><p><strong>Conclusion: </strong>Over the past 20 years, global publications on the relationship between NASH and DM have grown rapidly. The current research hotspots focus on weight loss, and the reduction of blood glucose and fibrosis in NASH. Maintaining a healthy diet, exercising regularly, taking appropriate medication, and being vigilant about complications are essential for delaying the progression of NASH and DM. These are also the primary future directions of research.</p><p","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145115888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}